Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus

J Clin Oncol. 2011 Sep 10;29(26):e727-30. doi: 10.1200/JCO.2011.36.2095. Epub 2011 Aug 15.

Authors

Sarina A Piha-Paul¹, Philip R Cohen, Razelle Kurzrock

Affiliation

¹ Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA.

PMID: 21844496
DOI: 10.1200/JCO.2011.36.2095

No abstract available

MeSH terms

Aged
Humans
Male
Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / therapeutic use*
Salivary Ducts*
Salivary Gland Neoplasms / drug therapy*
Salivary Gland Neoplasms / pathology
Sirolimus / administration & dosage
Sirolimus / analogs & derivatives*
Sirolimus / therapeutic use
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Skin Neoplasms / secondary*
TOR Serine-Threonine Kinases / antagonists & inhibitors

Substances

Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors
temsirolimus
TOR Serine-Threonine Kinases
Sirolimus